| Name | Title | Contact Details |
|---|
EnteroMedics® Inc. is the developer of vBloc® neurometabolic therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. vBloc Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals. vBloc Therapy is now approved by the Food and Drug Administration for weight loss in adults with a BMI of 40 to 45 kg/m2 or a BMI of 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels.* *Individuals should have first tried to lose weight by diet and exercise in a supervised program within the last 5 years before receiving the Maestro System.
DURECT Corporation is a Cupertino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NanoDx Inc. is a privately held medical device company developing novel and rapid point-of-care technologies for the objective diagnosis and management of concussion and other traumatic brain injury (TBI).
Scholten Surgical Insturments is a Lodi, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MyLife Hearing Aids Centers is a Portsmouth, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.